Moderna MRNA appears to have experienced a rollercoaster in the biotech market, facing both praise and criticism. Although RFK Jr. is reported to be looking for funds and the company's patents are under scrutiny, its cash reserves are potentially its lifeline. The
patent war with mRNA continues to escalate with a critical verdict anticipated by
2025. Amidst this chaotic situation, Moderna received a
$590 million grant from HHS to develop
mRNA vaccines against pandemic flu threats. Ambitious plans have been announced for a
cancer vaccine launch by
2027, while recent studies indicate promising results for the company's
mpox mRNA vaccine. Moderna looks to enhance its manufacturing efficiencies, with three new plants scheduled to go live in 2025. The company's
RSV vaccine studies were halted due to safety concerns, notwithstanding, Moderna has triumphed against
Pfizer and BioNTech in a patent disagreement in a German court. Despite negative remarks on its financial performance, Moderna remains a stock with a potential to skyrocket by 2025.
Moderna MRNA News Analytics from Wed, 12 Jun 2024 07:00:00 GMT to Sat, 29 Mar 2025 20:18:06 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
